Ticker

No recent analyst price targets found for ULBI.

Latest News for ULBI

Zacks Initiates Coverage of Ultralife With Underperform Recommendation

Discover why Zacks rates Ultralife as "Underperform", being the first on Wall Street to initiate coverage on the stock. Explore ULBI's struggles with execution risks, margin pressure and commercialization delays that could delay its earnings recovery.

Zacks Investment Research • Jul 16, 2026
Ultralife Q1 Earnings Call Highlights

Ultralife NASDAQ: ULBI reported a first-quarter loss for fiscal 2026 as lower sales, production disruptions and higher one-time costs weighed on results, even as management pointed to a record backlog and new product activity as signs of future growth.

MarketBeat • May 9, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for ULBI.

No House trades found for ULBI.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top